一種新型喜樹堿衍生物納米乳的制備性質(zhì)考察及其抗腫瘤活性研究

1、Formulation development and anti-tumor activity of a lipid nanoemulsion for a novel hydrophobic anticancer drugMin Han,1 Cai-Xia He,1 Qiu-Li Fang,1 Xiao-Chun Yang,2 Qing-Qing Zhao,1 Qiao-Jun He,2 Yong-Zhou Hu,3 Wen-Quan Liang,1 Bo Yang,2 Jian-Qing Gao1,Corresponding author: J.Q.Gao: Tel/Fax: +86-571

2、-8820-8437. E-mail:gaojianqing.1 Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.2 Institute of Pharmacology & Toxicology and Biochemical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.3Institute of Material

3、 Medica, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.ABSTRACT: OBJECTIVE An oil/water nanoemulsion was developed in the present study to enhance the solubility, stability and anti-tumor activity of a novel 10-methoxy-9-nitrocamptothecin (MONCPT). METHODS MONCPT nanoemuls

4、ion was prepared using Lipoid E80 and cremophor EL as main emulsifiers by microfluidization. The droplet size of the nanoemulsion was measured by dynamic light scattering. In vitro drug release was monitored by membrane dialysis. Kinetics of MONCPT transformed into carboxylic salt was performed in p

5、hosphate buffer at different pH. Hemolysis of MONCPT nanoemulsion was conducted in rabbit erythrocytes. Solubilization character of MONCPT in nanoemulsion was experimented using nile red as a solvatochromic probe. In vitro cytotoxicity of the nanoemulsion was measured in A549 and S180 cells using Su

6、lforhodamine B protein stain method, and suppression rate of tumor growth was investigated in S180-bearing mice. The cell cycle effects of MONCPT nanoemulsion on S180 cells were analyzed by flow cytometry. Distribution of the nanoemulsion in A549 cells was also investigated by fluorescence

7、 image. RESULTS MONCPT is incorporated in the nanoemulsion in form of lactone with concentration of 489 µg/mL, more than 200 folds higher than that in water. Experiments using nile red as a solvatochromic probe indicated that more MONCPT might be located in the interfacial surfactant layer of t

8、he nanoemulsion than that in discrete oil droplet or continuous aqueous phase. Nanoemulsion could release MONCPT in a sustained way, and it was further shown to notably postpone the hydrolysis of MONCPT with longer hydrolysis half-life time (11.38 h) in nanoemulsion at pH 7.4 than that of MONCPT sol

9、ution (4.03 h). No obvious hemolysis was caused by MOCPT nanoemulsion in rabbit erythrocytes. MONCPT nanoemulsion showed a marked increase in cytotoxic activity, 23.6 folds and 28.6 folds in S180 cells and A549 cells respectively via arresting the cell at G2 phase, compared to that induced by MONCPT

10、 injection. It correlated well to the in vivo anti-tumor activity of MONCPT nanoemulsion with suppression rate of 93.6%, while that of MONCPT injection was only 24.2% at the same dosage. Moreover, nanoemulsion exhibited enhanced capability of delivering drug into malignant cell's nucleus in vitr

11、o. CONCLUSION The nanoemulsion prepared exhibited an improved MONCPT solubility, stability and anti-tumor activity, providing a promising carrier for cancer chemotherapy using MONCPT.KEY WORDS: emulsion; in vitro release; stability; nile red; anti-tumor; cell cycle一種新型喜樹堿衍生物納米乳的制備、性質(zhì)考察及其抗腫瘤活性研究韓旻1，何

12、彩霞1，方秋黎1，楊小春2，趙青青1，何俏軍2，胡永洲3，梁文權(quán)1，楊波2，高建青1，*（1. 浙江大學(xué)藥學(xué)院藥物制劑研究所；2. 浙江大學(xué)藥學(xué)院藥理毒理與生化藥學(xué)研究所；3. 浙江大學(xué)藥學(xué)院藥物研究所。杭州 310058）摘要：目的 制備一種新型喜樹堿衍生物（10-甲氧基-9-硝基喜樹堿）的納米乳劑，以提高藥物的溶解度、穩(wěn)定性和抗腫瘤活性。方法 以Lipoid E80和cremophor EL為乳化劑，通過微射流制備載藥納米乳劑，考察乳劑的粒徑、開環(huán)動(dòng)力學(xué)、體外溶出和溶血情況。以尼羅紅熒光探針作為溶劑化變色染料探討乳劑的增溶性質(zhì)，研究藥物乳劑的體內(nèi)外抗腫瘤活性，并通過流式分析考察乳劑對(duì)S18

13、0細(xì)胞周期的影響，另外以尼羅紅為熒光探針研究乳劑對(duì)其在A549細(xì)胞核內(nèi)分布的影響。結(jié)果 乳劑中藥物濃度為489 µg/mL，顯著高于其水中溶解度（2.61µg/mL），深入研究發(fā)現(xiàn)更多的藥物被增溶在乳劑中的油水界面膜內(nèi)。乳劑可以延緩藥物的釋放，另外在pH 7.4緩沖液中，乳劑中藥物的開環(huán)半衰期（11.38 h）較其水溶液（4.03 h）顯著延長(zhǎng)。乳劑對(duì)體外家兔血紅細(xì)胞無(wú)明顯溶血作用，并可通過作用于細(xì)胞的G2期（S180細(xì)胞）發(fā)揮其良好的體內(nèi)外抗腫瘤活性。與其注射液相比，其體外對(duì)S180和A549細(xì)胞的殺傷作用可分別提高23.6和28.6倍，乳劑的S180小鼠體內(nèi)抑瘤率為93

14、.6%，明顯高于其注射劑的24.2%。另外與注射劑相比，乳劑還顯示出一定的細(xì)胞核內(nèi)遞送藥物的能力。結(jié)論 所制備的乳劑可明顯提高10-甲氧基-9-硝基喜樹堿的溶解度、穩(wěn)定性和抗腫瘤活性。關(guān)鍵詞：乳劑；體外溶出；穩(wěn)定性；尼羅紅；抗腫瘤；細(xì)胞周期1 INTRODUCTIONKnown as important anticancer drugs, camptothecin derivatives, such as irinotecan, GG-211, dx-8951f, topotecan, 9-nitrocamptothecin and 10-hydroxycamptothecin have at

15、tracted extensive attention for their binding and inhibition of topoisomerase (Topo ) which distributed extensively in tumor cells 1, 2. However, the response rate and overall survival rate have not been improved substantially for most of them compared to that of camptothecin 3. Although 9-nitrocamp

16、tothecin possesses a potent activity with low toxicity, difficult in preparing limits its research and clinical application. The introduction of a nitro at position 9, such as 9-nitrocamptothecin, has shown satisfactory activity with low toxicity. However, 9-nitrocamptothecin was difficult to prepar

17、e by nitration of camptothecin because 12-nitrocamptothecin was the main product 4. In contrast, 10-alkoxy-9-nitrocamptothecin (MONCPT) could easily be prepared from 10-hydroxycamptothecin 5,6, which possesses a potent anti-tumor activity due to its regulation of cell cycle or potential property for

18、 inhibiting angiogenesis as revealed in our previous studies 7,8. However, poor solubility and stability of MONCPT like other camptothecin derivatives limits its further in vivo researches. Although transformation of a lactone ring contained in camptothecin derivatives into an open-ring hydroxy carb

19、oxylic acid in alkaline solvents may enhance its solubility dramatically, an inevitable decrease in activity or increase in toxicity makes it inappropriate for application 9-11.Meanwhile, considerable emphasis has been given to develop emulsion systems as drug carrier system because of its improved

20、solubilization for water-insoluble and/or oil insoluble active compounds, modified drug release characteristic, protecting drug from transformation and delivering drugs into some tissues specifically after intravenous administration 12-16. Being a class of stable emulsions composed of discrete oil p

21、hase and continuous aqueous phase separated by a monolayer of surfactants with particle diameter usually less than 100 nm 17, nanoemulsion have been shown to increase bioavailability and efficacy of a number of compounds such as insulin and paclitaxel 18,19. In present study, nanoemulsion incorporat

22、ing MONCPT was developed to achieve a potential parenteral delivery system for MONCPT. The investigation focuses on the release and stability of the drug encapsulated in nanoemulsion, as well as its anti-tumor activity both in vitro and in vivo. Furthermore, nile red was used as a solvatochromic pro

23、be to investigate the mechanism of solubility enhancement. In present study, nanoemulsion incorporating MONCPT was developed to achieve a potential parenteral delivery system for MONCPT. The investigation focuses on the release and stability of the drug encapsulated in nanoemulsion, as well as its a

24、nti-tumor activity both in vitro and in vivo. Furthermore, nile red was used as a solvatochromic probe to investigate the mechanism of solubility enhancement, and the distribution of nanoemulsion in cell nucleus.2 MATERIALS AND METHODS2.1 MaterialsLipoid E80 was purchased from Lipoid AG (Ludwigshafe

25、n, Germany), which consists of 82.4% phosphatidylcholine and 8.0% phosphatidyl ethandamine as mentioned in manufactures specification. Cremophor EL was furnished by BASF (Parsippany, NJ.USA). Soybean oil was purchased from Tielingbeiya pharmaceutical Co. (Tieling, China). Glycerol formal was kindly

26、provided by Elementis (London, England). Sulforhodamine B (SRB) was purchased from Sigma (St Louis, MO, USA). All other chemicals and reagents used were of analytical or chromatographic grade.2.2 Assay of MONCPTHigh performance liquid chromatography (HPLC) system was composed of an Agilent G1310A pu

27、mp, an Agilent G1314A VWD detector and a Diamonsil® C18 reverse phase column(4.6×150mm, 5um, Dikma Technologies). The mobile phase consisted of acetonitrile-1% triethylamine in distilled water (32:68) with pH adjusted to 5.5 by glacial acetic acid. Chromatography was performed at 40 and wa

28、velength was set to 383nm. 2.3 Preparation of MONCPT nanoemulsion0.27 g lipoid E80, 0.36 g cremophor EL, 0.15 g ethanol, and 15 mg MONCPT were dissolved into 1.8 g soybean oil at 70. 6.0 g PEG 400, 0.66 g glycerol and 6.0 g glycerol formal were dissolved in 15 g purified water as aqueous phase. Afte

29、r mixing aqueous phase with oil phase at 70, The coarse nanoemulsion was obtained by homogenization using a FJ-200 high shear mixer (12000 rpm, 3 min) (shanghai specimen model Ltd., shanghai, china), then it was further emulsified in a M110L microfluidizer system (Microfluidics Co., American）under 1

30、0 microfluidization cycles at a pressure of 12,000 psi at 4 to obtain final nanoemulsion with MONCPT concentration of 0.489 mg/ml. Ethanol was used as co-surfactant, and PEG 400, glycerol formal were applied as solubilizer and stabilizer in the formulation. 2.4 Characteristic evaluation of MONCPT an

31、d nanoemulsionSolubility of MONCPT in different solvents was measured by shaking 3 ml solvents added with excess amount of MONCPT at 37 for 48 h away from light. The suspension was centrifuged at 8,000×g for 10 min and filtered through a 0.22 µm membrane, then MONCPT concentration in sampl

32、es was determined by HPLC. N-octanol/water partition coefficient (P) of MONCPT was determined by shaking-flask method.Following appropriate dilution with distilled water, MONCPT nanoemulsion droplet size was determined by dynamic light scattering (MALVERN Nano ZS®, Malvern, UK). The nanoemulsio

33、n profiles was checked under JEM1230 electronmicroscope (Japan Electron Optics Laboratory, Tokyo, Japan) and pH was measured using a pH-meter at room temperature.In vitro release of MONCPT was monitored by reversed-dialysis bag method at 37 under shaking at 75 rpm using phosphate-buffered saline (PB

34、S) as a sink solution at pH 7.0 20. Dialysis bag with a MW cut-off between 12k and 14k was filled with 10 mL PBS and immersed into 250 mL PBS to equilibrium for 12h, then 1 mL MONCPT nanoemulsion, 1 mL MONCPT injection (Distilled water dissolved MONCPT at 0.5 mg/mL with pH adjusted to 8.0 by NaOH af

35、ter addition of 0.1 EDTA and 1 NaHSO3, and then filtered through 0.22 µm membrane), and 1 mL MONCPT water solution (0.5 mg/mL, containing 5% DMSO) were added into 250 mL blank PBS outside of dialysis bag, respectively. At predetermined intervals, 200 µL samples were taken from release medi

36、um inside of dialysis bag followed by immediate replacement with 200 µL fresh PBS. Drug release profiles (% drug released vs time) were generated. Assuming 100% drug release, the concentration of MONCPT in the PBS will be 2 µg/mL which is lower than MONCPT water solubility 2.61 µg/mL.

37、 Transformation kinetics of MONCPT in PBS at different pH was investigated. 20 µL MONCPT water solution (containing 25% DMSO) (1 mg/mL) or 15 µL MONCPT nanoemulsion (0.489 mg/mL) was added up to 10ml with PBS at various pH (5.5, 6.4, 7.4, 8.0). 50 µl samples was taken at pre-determine

38、d intervals and rapidly measured by HPLC.2.5 Hemolysis studyAfter blood clotting by rotation under assist of glass beads, blood samples, obtained from rabbit arteria auricularis, were immediately separated by centrifugation at 2000 rpm for 10 min and washed three times with saline. Then, erythrocyte

39、s were collected and diluted with saline to 2% suspension. 0.3 mL MONCPT nanoemulsion or injection was added to tubes and the volume was adjusted to 2.5 ml with saline, and then incubated with 2.5 mL 2% erythrocyte suspension at 37. After 3 h of incubation, the samples were centrifuged for 10 min at

40、 2000 rpm. The percentage of hemolysis was determined by comparing the absorbance at 414 nm of the supernatant with that of positive control samples totally hemolyzed with distilled water (taken as 100%), and hemolysis induced with saline was used as negative control. 2.6 Solubility characteristic o

41、f nanoemulsionNile red (Sigma, St Louis, MO, USA) was used as a solvatochromic and hydrophobic probe to investigate the solubility characteristic of the nanoemulsion. An excess amount of nile red powder was added into soybean oil that was used as oil phase in the nanoemulsion, solution with the same

42、 components of aqueous phase in the nanoemulsion, and nanoemulsion that was prepared as described in the text with MONCPT removed, respectively. These solutions were sonicated for 20 min and were left for 24 h away from light, then the supernatants were obtained by centrifugalization at 12 000 rpm f

43、or 10 min. After standard curve of nile red dissolved in 1-propanol (Beijing chemical plant, China) was established by UV-VIS absorbance at 546 nm in a TU-1800PC Scanning Spectrophotometer (Puxi GP Co. BeiJing, China), nile red concentration in the supernatants diluted by 1-propanol appropriately wa

44、s determined. On the other hand, absorbance spectra of nile red in the above solutions was also performed to explore the location site of nile red in the nanoemulsion according to the approach described previously 21. 2.7 In vitro and in vivo anti-tumor activityA549 and S180 cell lines were obtained

45、 from ATCC and grown in Dulbeccos modified Eagles medium with 10% fetal calf serum in 96-well cell-culture plates under 5% CO2 at 37 for 48 h. The in vitro cytotoxicity of the nanoemulsion, injection and water solution (containing 1 DMSO) of MONCPT in A549 and S180 cells was measured using Sulforhod

46、amine B (SRB) protein stain method 22. MONCPT-free nanoemulsion (same composition of the nanoemulsion without MONCPT) was also detected to evaluate the potential side effects of the components in the nanoemulsion.Male mice (10 mice per group) were subcutaneously implanted with 0.2 mL S180 ascites tu

47、mor cells (1×106 cells/mL). 24 h after implantation, mice were randomly sorted into treatment groups and were administrated intravenously (i.v.) with saline (10 mL/kg), MONCPT nanoemulsion (5 mg/kg), MONCPT injection (5 mg/kg), intramuscularly (i.m.) with MONCPT oil (tea oil, 10mg/kg) suspensio

48、n, and intraperitoneally (i.p.) with cyclophosphamide (30mg/kg) once every two days. Tumors were removed from sacrificed mice at day 16 post inoculation, and were weighed to evaluate anti-tumor activity of various treatments. The percentage of tumor growth was calculated as equation followed:Suppres

49、sion rate (SR×100%)=Where Wc and Wt are the mean tumor weights (grams) of the control and the treated mice respectively. 2.8 DNA cell cycle analysis by flow cytometryTo analysis cell cycle, S180 cells (5×104 cells/ml, 5 ml) were cultured in 25 cm2 flasks, trea

50、ted with the nanoemulsion incorporating MONCPT (0.2mM, 0.4mM, 0.8mM) for 24h. Cells were then harvested and quickly washed twice with ice-cold PBS, and cell pellets were resuspended in 1 ml of 0.1% sodium citrate containing propidium iodide (PI) 0.05 mg and 50.0 g RNase for 30 min at room temperatur

51、e in the dark. Flow cytometry was performed on a Becton Dickinson FACScan, with collection and analysis of data performed using Becton Dickinson CELLQuest software.2.9 Fluorescence microscopyNile red was used as a substitute for MONCPT to prepare nanoemulsion at a final concentration of 0.1 mg/mL, w

52、hich was employed to investigate the influence of nanoemulsion on nile red uptake in tumor cells.After being incubated with nile red nanoemulsion that had been diluted to 250 times volume by PBS for 0.5 h, A549 cells were washed with PBS for three times to remove nile red that had not been absorbed.

53、 In order to demonstrate the intracellular location of nile red, which could emit red fluorescence at an excitation wavelength of 543 nm, the same A549 cells were further incubated with Hoechst 33342 (Beyotime institute of biotechnology, Jiangsu, China) in Hanks Balanced Salt Solution (HBSS) (2 

54、1;g/mL) for 10 min to specifically stain the cell nucleus blue with an excitation wavelength of 346 nm. Same conduction was performed for nile red in HBSS (containing 1% DMSO) as control to nile red nanoemulsion. After incubation, the A549 cells were monitored by fluorescence microscopy, and images

55、of red fluorescence of nile red and blue fluorescence of hoechst 33342 were overlapped to investigate the intracellular distribution of nile red.2.10 Statistical analysisValues are expressed as mean±SD. Statistical comparisons were made by using two-tailed Students t-test and comparisons among

56、more than three groups were performed by using one-way ANOVA. P<0.05 was considered to be significant.3 RESULTS3.1 Characteristics of MONCPT and nanoemulsionAs determined by HPLC, solubility of MONCPT in water, methanol, n-octanol, Migylol 812, glyceryl trioleate and soybean oil is 2.61, 69.47, 1

57、9.46, 13.71, 17.18 and 17.47 µg/mL respectively, and N-octanol/water partition coefficient (P) is 3.82±1.31, which indicates the insolubility of MONCPT in both hydrophilic and hydrophobic solvents. Content of MONCPT incorporated in the nanoemulsion was determined to be 489µg/mL, which

58、 is significantly higher than that in water and oils as mentioned above. pH of the MONCPT nanoemulsion was tested to be 5.78, protecting MONCPT from transformation in alkaline circumstance. The image of MONCPT nanoemulsion observed under transmission electron microscope was shown in Figure 1(A). The

59、 particle size measured by dynamic light scattering ranged from 45 to 95 nm with a mean diameter of 67 nm.Release kinetics of MONCPT from the nanoemulsion or injection was investigated using MONCPT water solution as control. There was no significant difference in release profiles between injection and water solution that release MONCPT rapidly as shown in Figure 1(B). While the nanoemulsion showed a relatively sustained way with less than 70% MONCPT being released over 4 h.It is known that lactone form is the main active form of camptothecin or its derivatives. Therefore, in